ArticleCureus2025
Seroprevalence of Varicella-Zoster Virus and the Need for Herpes Zoster Vaccination Among Adults in Saudi Arabia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChickenpox is caused by the varicella-zoster virus (VZV), which can reactivate later in life, leading to herpes zoster (shingles). The varicella vaccine has been integrated into childhood immunization programs in certain regions, contributing to the control and prevention of the disease. However, there remains uncertainty regarding the seroprevalence of varicella among adults, as well as concerns about vaccination rates and public awareness of its importance.
objectiveThe objective of this study is to estimate the seroprevalence of varicella among Saudi adults who may require vaccination against varicella and herpes zoster.
methodsThis descriptive cross-sectional study involved 209 Saudi adults aged 18 years and older in Riyadh. Data were collected using a validated questionnaire and serological testing for VZV-IgG antibodies. Statistical analyses were conducted to explore the relationships between seroprevalence, vaccination history, and demographic factors.
resultsThe study, comprising primarily young adults aged 18-47 years (83.3%) with a nearly equal gender distribution (52.2% male, 47.8% female), found that 81.1% of participants were serologically immune to VZV. Immunity was higher among males (84.4% vs. 79% in females) and older participants (89.7% in those ≥38 years vs. 78% in those <38 years). A positive history of varicella infection or vaccination increased the likelihood of VZV-IgG positivity by nine times compared to deniers and four times compared to unsure participants. History-based immunity assessment had a sensitivity of 87.1% and specificity of 57.7%.
conclusionThe study highlights a high prevalence of serological immunity to VZV among Saudi adults. While a positive history strongly predicted immunity, the limited validity of history-based assessments underscores the need for serological confirmation in some cases. Despite widespread immunity and consequently the risk of herpes zoster, the low uptake of herpes zoster vaccination among eligible individuals with a history of shingles points to a gap in preventive healthcare. These findings emphasize the importance of targeted public health efforts to improve vaccination coverage among adults, particularly for herpes zoster.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.